Guardant Health Inc.’s genomic data-powered technologies for accelerating drug development infringe Tempus AI Inc.’s “groundbreaking” cancer research patents, according to a federal lawsuit.
Guardant Accused of Infringing Tempus AI Cancer Research Tech
